Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...

Zoryve is now approved to treat atopic dermatitis, plaque psoriasis in adults and children, as well as seborrheic dermatitis.

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing CohortInterim Data from Atopic Dermatitis Trial ...

In a completed Phase 2a, single-arm, proof-of-concept trial in the United States in 22 patients with moderate to severe atopic dermatitis, BSI-045B was observed ... joins as Executive Vice President, ...

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

The licensing deal with Biosion involves an experimental treatment for severe asthma and skin disorder known as atopic ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

So for long term treatment of allergies, or I should say allergy symptoms, because that's what these medications are treating, they're treating the symptoms of allergies, they're as effective as ...